Uziel A, Goubert J L
Nouv Presse Med. 1982 Nov 18;11(46):3456-8.
Cochlear and vestibular ototoxicity of dibekacin was evaluated in 27 patients treated with aminoglycoside after surgery on head and neck cancer. The treatment was administered intramuscularly or intravenously during 13 days at the schedule of 3 mg/kg per day. Cochlear and vestibular functions were tested by audiometry and electronystagmography before the administration of the antibiotic and on the 14th, 30th day, and for certain patients on the 4th month after the start of the treatment. No cochlear ototoxicity was found after the dibekacin treatment. On the other hand, the dibekacin treatment produced minor abnormalities of ENG (irritative pattern).
对27例头颈部癌术后接受氨基糖苷类药物治疗的患者评估了地贝卡星的耳蜗和前庭耳毒性。治疗方案为每天3mg/kg,肌肉注射或静脉注射,持续13天。在使用抗生素前以及治疗开始后的第14天、30天,部分患者在第4个月时,通过听力测定和眼震电图测试耳蜗和前庭功能。地贝卡星治疗后未发现耳蜗耳毒性。另一方面,地贝卡星治疗产生了轻微的眼震电图异常(刺激性模式)。